Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Insulin like growth factor-1 (IGF-1) is established as an anabolic factor that can induce skeletal muscle growth by activating the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway. Although this signaling pathway has been the subject of much study, the molecular mechanisms linking IGF-1 binding to mTOR activation remain poorly defined in muscle. The present study aimed to test the hypothesis that IGF-1 activation of mTOR in C2C12 myotubes requires a phosphorylation-dependent, altered distribution of the tuberous sclerosis complex (TSC)1/TSC2 complex from the membrane to the cytosol. We found that IGF-1 treatment does not affect complex formation between TSC1 and TSC2, but rather IGF-1 induces an altered distribution of the TSC1/TSC2 complex in C2C12 myotubes. In response to IGF-1 treatment, there was a relative redistribution of the TSC1/TSC2 complex, composed of TSC1 and phosphorylated TSC2, from the membrane to the cytosol. IGF-1-stimulated TSC1/TSC2 phosphorylation and redistribution were completely prevented by the phosphoinositide 3-kinase inhibitor wortmannin, but were not with the downstream mTOR inhibitor, rapamycin. When a nonphosphorylatable form of TSC2 (S939A) was overexpressed, phosphorylation-dependent binding of the scaffold protein 14-3-3 to TSC2 was diminished and no redistribution of the TSC1/TSC2 complex was observed after IGF-1 stimulation. These results indicate that TSC2 phosphorylation in response to IGF-1 treatment is necessary for the altered distribution of the TSC1/TSC2 complex to the cytosol. We suggest that this translocation is likely critical for mTOR activation by dissociating the interaction between the GTPase activating protein activity of the TSC1/TSC2 complex and its downstream target, Ras homolog enriched in brain.
Miyazaki
Mitsunori
M
Center for Muscle Biology, Department of Physiology, University of Kentucky, Lexington, USA.
McCarthy
John J
JJ
Esser
Karyn A
KA
D048948:14-3-3 Proteins / Q000378:metabolism; D000818:Animals; D002454:Cell Differentiation; D002460:Cell Line; D004789:Enzyme Activation; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D051379:Mice; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D011485:Protein Binding; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D021381:Protein Transport; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D058570:TOR Serine-Threonine Kinases; D000077004:Tuberous Sclerosis Complex 1 Protein; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins / Q000378:metabolism*
D048948:14-3-3 Proteins; D007334:Insulin-Like Growth Factor I; D047908:Intracellular Signaling Peptides and Proteins; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; D000077004:Tuberous Sclerosis Complex 1 Protein; D000077005:Tuberous Sclerosis Complex 2 Protein; D025521:Tumor Suppressor Proteins; C000624651:Tsc1 protein, mouse; C000624654:Tsc2 protein, mouse; C546843:mTOR protein, mouse
Biochem Soc Trans. 2009 Feb;37(Pt 1):217-22
19143635
J Biol Chem. 2002 Aug 23;277(34):30958-67
12045200
J Appl Physiol (1985). 2002 Sep;93(3):1168-80
12183515
J Biol Chem. 2003 Jan 24;278(4):2089-92
12468542
J Neurochem. 2007 Mar;100(6):1480-93
17348861
J Biol Chem. 2002 Oct 18;277(42):39417-24
12176984
J Biol Chem. 2003 Apr 18;278(16):13663-71
12582162
Nat Cell Biol. 2002 Sep;4(9):648-57
12172553
Genes Dev. 2003 Aug 1;17(15):1829-34
12869586
J Appl Physiol (1985). 2009 Apr;106(4):1367-73
19036895
Biochem J. 2008 Jun 1;412(2):179-90
18466115
J Neurochem. 2009 Jun;109(5):1440-51
19453943
Mol Cell. 2002 Jul;10(1):151-62
12150915
Cell. 2005 Apr 22;121(2):179-93
15851026
Biochem J. 2004 Jun 15;380(Pt 3):795-804
15030312
J Biol Chem. 2002 Sep 20;277(38):35364-70
12167664
J Biol Chem. 2006 Mar 31;281(13):8313-6
16464865
J Cell Biol. 2006 Apr 24;173(2):279-89
16636147
Nat Rev Mol Cell Biol. 2003 Feb;4(2):117-26
12563289
Nat Cell Biol. 2002 Sep;4(9):658-65
12172554
Am J Physiol Cell Physiol. 2009 Mar;296(3):C583-92
19129461
Am J Physiol Cell Physiol. 2005 Dec;289(6):C1457-65
16079186
Biotechniques. 2003 Nov;35(5):936-8, 940
14628666
Curr Biol. 2003 Aug 5;13(15):1259-68
12906785
Genes Dev. 2004 Oct 15;18(20):2479-84
15466161
Cancer Res. 2002 Nov 15;62(22):6475-80
12438239
Nat Cell Biol. 2002 Sep;4(9):699-704
12172555
Nat Cell Biol. 2001 Nov;3(11):1009-13
11715022
Cancer Res. 2007 Aug 1;67(15):7106-12
17671177
J Appl Physiol (1985). 2007 Jul;103(1):378-87
17332274
Nat Cell Biol. 2001 Nov;3(11):1014-9
11715023
Mol Cell. 2003 Jun;11(6):1457-66
12820960
Cell. 2003 Nov 26;115(5):577-90
14651849